{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 38 of 169', 'Panel 6 Objectives and endpoints: initial treatment period (continued)', 'Objectives', 'Endpoints', 'Other objectives', 'Other endpoints', 'To evaluate the efficacy over time of', 'IGA 0/1 at each scheduled assessment until', 'tralokinumab on severity and extent of', 'Week 14', 'AD, itch, and health-related quality of', 'EASI75 at each scheduled assessment until', 'life compared with placebo.', 'Week 14', 'Change in SCORAD from baseline to each', 'scheduled assessment until Week 14', 'Change from baseline to each week through', 'Week 1 to 15 in Worst Daily Pruritus NRS (weekly', 'average)', 'Reduction of Worst Daily Pruritus NRS (weekly', 'average) of at least 4 from baseline to each week', 'through Week 1 to 15', 'Change in DLQI score from baseline to each', 'scheduled assessment until Week 14', 'To evaluate the efficacy of', 'Reduction of Worst Daily Pruritus NRS (weekly', 'tralokinumab compared with placebo', 'average) of at least 3 from baseline to Week 2', 'on patient-reported outcomes and', 'Change from baseline to Week 16 in', 'health care resource utilisation.', 'Eczema-related Sleep NRS weekly average', 'Change from baseline to Week 16 in HADS', 'HADS anxiety and HADS depression scores <8', 'at', 'Week 16 in subjects with baseline HADS anxiety', 'or HADS depression subscale scores of >8', 'Change from baseline to Week 16 in POEM', 'Reduction from baseline to Week 16 of POEM of', '>4 points among subjects with baseline POEM >4', 'Change from baseline to Week 16 in SF-36', 'Change from baseline to Week 16 in EQ-5D-5L', 'Change from baseline to Week 16 in WPAI-GH', 'Treatment satisfaction (TSQM) at Week 16', 'To evaluate the incidence of skin', 'Skin colonisation of S. aureus at Week 16 among', 'colonisation with Staphylococcus', 'subjects who are positive at baseline', 'aureus in tralokinumab treated patients', 'compared with placebo at Week 16.', 'AD, atopic dermatitis; AE, adverse event; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and', 'Severity Index; EASI50, at least 50% reduction in EASI score; EASI75, at least 75% reduction in EASI score;', 'EASI90, at least 90% reduction in EASI score; EQ-5D-5L, EuroQoL 5-Dimension Health Questionnaire 5', \"Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator's Global Assessment; NRS, numeric\", 'rating scale; POEM, Patient Oriented Eczema Measure; SAE, serious adverse event; SCORAD, Scoring Atopic', 'Dermatitis; SCORAD50, at least 50% reduction in SCORAD score; SCORAD75, at least 75% reduction in', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 39 of 169', 'SCORAD score; SF-36, 36-Item Short Form Health Survey; TSQM, Treatment Satisfaction Questionnaire for', 'Medication; WPAI-GH, Work Productivity and Activity Impairment - General Health.', '6.2 Maintenance treatment period of Weeks 16 to 52 for responders at', 'Week 16', 'Panel 7 Objectives and endpoints: maintenance treatment period', 'Objectives', 'Endpoints', 'Maintenance objective', 'Maintenance endpoints', 'To evaluate maintenance of effect', 'IGA of 0/1 at Week 52 among subjects with IGA', 'with continued tralokinumab dosing', 'of 0/1 at Week 16 achieved without rescue', 'up to 52 weeks compared to placebo', 'medication after initial randomisation to', 'for subjects achieving clinical', 'tralokinumab', 'response at Week 16.', 'EASI75 at Week 52 among subjects with EASI75', 'at Week 16 achieved without rescue medication', 'after initial randomisation to tralokinumab', 'Other maintenance objectives', 'Other maintenance endpoints', 'To evaluate the safety and tolerability', 'AE/SAE frequency by preferred term', 'of tralokinumab when used to treat', 'Frequency of anti-drug antibodies', 'moderate-to-severe AD for 52 weeks.', 'To evaluate time to relapse in the', 'Time to relapse applying IGA of 0/1', 'maintenance treatment period.', 'Time to relapse applying EASI75', 'To evaluate the efficacy of', 'IGA of 0/1 at Week 52 among subjects with', 'maintenance treatment up to Week 52', 'EASI75 and IGA>2 at Week 16', 'among subjects randomised to the', 'maintenance treatment period with', 'EASI75 and IGA>2 at Week 16.', 'To support the maintenance objective', 'IGA 0/1 or EASI75 at Week 52 among subjects', 'in the trial.', 'with IGA 0/1 or EASI75 at Week 16 achieved', 'without rescue medication', 'AD, atopic dermatitis; AE, adverse event; EASI75, at least 75% reduction in Eczema Area and Severity Index', \"score; IGA, Investigator's Global Assessment; SAE, serious adverse event.\", 'The maintenance endpoints of IGA 0/1 and EASI75 at Week 52 for subjects achieving clinical', 'response at Week 16 without rescue medication are considered secondary endpoints. The', 'additional maintenance endpoints are considered other endpoints. In Japan, the maintenance', 'endpoints of IGA 0/1 and EASI75 at Week 52 for subjects achieving clinical response at', 'Week 16 without rescue medication are evaluated as primary maintenance endpoints. This', 'regulatory requirement will have no impact on the analysis since an adjustment for', 'multiplicity is implemented for these 2 endpoints (Panel 15).', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}